BR9813998A - Novos derivados de piridazina e produtos medicinais contendo os mesmos como ingredientes efetivos - Google Patents
Novos derivados de piridazina e produtos medicinais contendo os mesmos como ingredientes efetivosInfo
- Publication number
- BR9813998A BR9813998A BR9813998-3A BR9813998A BR9813998A BR 9813998 A BR9813998 A BR 9813998A BR 9813998 A BR9813998 A BR 9813998A BR 9813998 A BR9813998 A BR 9813998A
- Authority
- BR
- Brazil
- Prior art keywords
- group
- substituted
- effective ingredients
- pyridazine derivatives
- medicinal products
- Prior art date
Links
- 239000004615 ingredient Substances 0.000 title abstract 3
- 229940126601 medicinal product Drugs 0.000 title abstract 2
- 150000004892 pyridazines Chemical class 0.000 title abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 102000000589 Interleukin-1 Human genes 0.000 abstract 1
- 108010002352 Interleukin-1 Proteins 0.000 abstract 1
- 125000004450 alkenylene group Chemical group 0.000 abstract 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000023589 ischemic disease Diseases 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical class C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/18—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Patente de Invenção: <B>"NOVOS DERIVADOS DE PIRIDAZINA E PRODUTOS MEDICINAIS CONTENDO OS MESMOS COMO INGREDIENTES EFETIVOS"<D>. A presente invenção está relacionada a derivados de piridazina representados pela fórmula (1): Onde R1 representa um grupo aril (substituído, R2 representa um grupo fenil substituído na posição 4 por um grupo alcoxil inferior ou um grupo alquiltio inferior, R3 representa um grupo alcoxil inferior, um grupo alquil inferior halogenado, um grupo cicloalquil inferior, um grupo aril (substituído), um grupo ariloxi (substituído), um resíduo de anel heterocíclico contendo nitrogênio (substituído), um grupo aminocarbonil (substituído) ou um grupo alquilcarbonil inferior, A representa uma união simples, um grupo alquileno inferior ou um grupo alquenileno inferior, X representa O ou S, e a linha tracejada indica que a união carbono-carbono entre a posição 4- e a posição 5- é uma união simples ou dupla, ou sais do mesmo; e também remédios contendo os mesmos como ingredientes efetivos. Esses compostos têm excelente atividade inibidora contra a produção de interleukin-1ß e são úteis como preventivos e terapêuticos para enfermidades do sistema imunológico, enfermidades inflamatórias, enfermidades isquêmicas e similares.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP31813297 | 1997-11-19 | ||
JP31813397A JP3999861B2 (ja) | 1997-11-19 | 1997-11-19 | 新規ピリダジン誘導体及びこれを有効成分とする医薬 |
PCT/JP1998/005023 WO1999025697A1 (fr) | 1997-11-19 | 1998-11-09 | Nouveaux derives de pyridazine et medicaments contenant ces composes comme principe actif |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9813998A true BR9813998A (pt) | 2000-09-26 |
Family
ID=26569260
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9813998-3A BR9813998A (pt) | 1997-11-19 | 1998-11-09 | Novos derivados de piridazina e produtos medicinais contendo os mesmos como ingredientes efetivos |
Country Status (21)
Country | Link |
---|---|
US (11) | US6348468B1 (pt) |
EP (2) | EP1043317B1 (pt) |
KR (1) | KR100626605B1 (pt) |
CN (1) | CN1142148C (pt) |
AT (1) | ATE428700T1 (pt) |
AU (1) | AU738595B2 (pt) |
BR (1) | BR9813998A (pt) |
CA (1) | CA2307111C (pt) |
DE (1) | DE69840755D1 (pt) |
DK (1) | DK1043317T3 (pt) |
ES (1) | ES2324126T3 (pt) |
HK (1) | HK1032969A1 (pt) |
HU (1) | HUP0100059A3 (pt) |
ID (1) | ID24166A (pt) |
MX (1) | MXPA00004955A (pt) |
NO (1) | NO316021B1 (pt) |
NZ (1) | NZ504045A (pt) |
PT (1) | PT1043317E (pt) |
RU (1) | RU2209813C2 (pt) |
TW (1) | TW502025B (pt) |
WO (1) | WO1999025697A1 (pt) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2307111C (en) * | 1997-11-19 | 2009-06-30 | Kowa Co., Ltd. | Novel pyridazine derivatives and drugs containing the same as the active ingredient |
TW587079B (en) * | 1998-09-25 | 2004-05-11 | Almirall Prodesfarma Ag | 2-phenylpyran-4-one derivatives |
JP2000247959A (ja) * | 1999-02-26 | 2000-09-12 | Kowa Co | ピリダジン−3−オン誘導体及びこれを含有する医薬 |
ES2162731B1 (es) * | 1999-06-04 | 2003-02-16 | Faes Fabrica Espanola De Produ | Nuevas arilpiperacilnilalquil-3(2h)-piridacinonas. |
PE20011333A1 (es) | 2000-03-16 | 2002-01-16 | Almirall Prodesfarma Ag | Derivados de 2-fenilpiran-4-ona como inhibidores de ciclooxigenasa 2 |
US6664256B1 (en) * | 2000-07-10 | 2003-12-16 | Kowa Co., Ltd. | Phenylpyridazine compounds and medicines containing the same |
AU761191B2 (en) * | 2001-05-24 | 2003-05-29 | Pfizer Products Inc. | Therapies for tissue damage resulting from ischemia |
EP1431293B1 (en) * | 2001-09-26 | 2011-06-08 | Kowa Co., Ltd. | Water-soluble phenylpyridazine derivatives and drugs containing the same |
MY128945A (en) * | 2002-04-16 | 2007-03-30 | Kowa Co | Solid dispersion composition |
US7074959B2 (en) * | 2002-08-01 | 2006-07-11 | New Mexico Highlands University | Methods and systems for remediating hydrazine-contaminated equipment and/or surfaces |
NZ541064A (en) * | 2003-03-07 | 2007-09-28 | Kowa Co | Benzofuran derivative |
CA2518227A1 (en) * | 2003-03-18 | 2004-09-30 | Kowa Co., Ltd | Water-soluble phenylpyridazine derivative and medicine containing the same |
US8105630B2 (en) * | 2003-04-29 | 2012-01-31 | Kowa Co., Ltd. | Composition containing medicine extremely slightly soluble in water being excellent in eluting property and method for preparation thereof |
MY147403A (en) * | 2003-04-29 | 2012-11-30 | Kowa Co | Composition containing medicine extremely slightly solube in water and method for preparation thereof |
WO2005012259A1 (ja) * | 2003-07-30 | 2005-02-10 | Kowa Co., Ltd. | オステオポンチン産生抑制方法 |
EP1604988A1 (en) * | 2004-05-18 | 2005-12-14 | Sanofi-Aventis Deutschland GmbH | Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals |
CN101031305A (zh) * | 2004-09-29 | 2007-09-05 | 兴和株式会社 | 类风湿性关节炎的预防和/或治疗药物 |
WO2006104172A1 (ja) * | 2005-03-29 | 2006-10-05 | Kowa Co., Ltd. | 関節リウマチの予防及び/又は治療薬 |
EP1920772A4 (en) * | 2005-08-31 | 2010-11-17 | Kowa Co | PROPHYLACTIC AND / OR THERAPEUTIC METHOD FOR COMBATING RHEUMATOID ARTHRITIS |
WO2007044796A2 (en) * | 2005-10-11 | 2007-04-19 | Nps Pharmaceuticals, Inc. | Pyridazinone compounds as calcilytics |
EP1941911A4 (en) * | 2005-10-28 | 2011-01-12 | Kowa Co | METHOD FOR PREVENTING AND / OR TREATING RHEUMATOID ARTHRITIS |
DE102005057924A1 (de) * | 2005-12-05 | 2007-06-06 | Merck Patent Gmbh | Pyridazinonderivate |
US20090203701A1 (en) * | 2006-06-29 | 2009-08-13 | Kowa Co., Ltd | Prophylactic and/or therapeutic agent for rheumatoid arthritis |
DE102006037478A1 (de) | 2006-08-10 | 2008-02-14 | Merck Patent Gmbh | 2-(Heterocyclylbenzyl)-pyridazinonderivate |
EP2099770B1 (en) | 2006-12-21 | 2015-06-10 | Sloan-Kettering Institute for Cancer Research | Pyridazinones and furan-containing compounds |
MX2009008059A (es) | 2007-01-29 | 2009-08-12 | Kowa Co | Agente para tratamiento de esclerosis multiple. |
WO2008111295A1 (ja) | 2007-03-09 | 2008-09-18 | Kowa Co., Ltd. | 全身性エリテマトーデスの予防及び/又は治療剤 |
DE102007025718A1 (de) | 2007-06-01 | 2008-12-04 | Merck Patent Gmbh | Pyridazinonderivate |
DE102007025717A1 (de) | 2007-06-01 | 2008-12-11 | Merck Patent Gmbh | Arylether-pyridazinonderivate |
DE102007032507A1 (de) | 2007-07-12 | 2009-04-02 | Merck Patent Gmbh | Pyridazinonderivate |
DE102007038957A1 (de) | 2007-08-17 | 2009-02-19 | Merck Patent Gmbh | 6-Thioxo-pyridazinderivate |
DE102007041115A1 (de) | 2007-08-30 | 2009-03-05 | Merck Patent Gmbh | Thiadiazinonderivate |
DE102007061963A1 (de) | 2007-12-21 | 2009-06-25 | Merck Patent Gmbh | Pyridazinonderivate |
DE102008019907A1 (de) | 2008-04-21 | 2009-10-22 | Merck Patent Gmbh | Pyridazinonderivate |
DE102008062826A1 (de) | 2008-12-23 | 2010-07-01 | Merck Patent Gmbh | Pyridazinonderivate |
DE102009003954A1 (de) | 2009-01-07 | 2010-07-08 | Merck Patent Gmbh | Pyridazinonderivate |
DE102009004061A1 (de) | 2009-01-08 | 2010-07-15 | Merck Patent Gmbh | Pyridazinonderivate |
TWI510241B (zh) | 2010-02-18 | 2015-12-01 | Vtv Therapeutice Llc | 苯基-雜芳基衍生物及其使用方法 |
WO2013097052A1 (en) | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
CN102603676B (zh) * | 2012-02-20 | 2014-02-12 | 徐江平 | 一种能避免呕吐反应的磷酸二酯酶4抑制剂 |
MA44674B1 (fr) | 2016-04-15 | 2020-06-30 | Abbvie Inc | Inhibiteurs de bromodomaine |
WO2018081381A1 (en) * | 2016-10-26 | 2018-05-03 | Proteostasis Therapeutics, Inc | Pyridazine derivatives, compositions and methods for modulating cftr |
WO2021163519A1 (en) | 2020-02-14 | 2021-08-19 | Fmc Corporation | Substituted 5,6-diphenyl-3(2h)-pyridazinones for use as fungicides |
TW202222163A (zh) * | 2020-08-14 | 2022-06-16 | 瑞士商先正達農作物保護公司 | 化學方法 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR206496A1 (es) | 1972-07-03 | 1976-07-30 | Riker Laboratories Inc | Procedimiento para la preparacion de 2-fenoxi-4-nitro-alquil o haloalquilsulfonanilidas |
WO1983000863A1 (en) * | 1981-09-11 | 1983-03-17 | Diamond Shamrock Corp | Antiinflammatory and analgetic 4-pyridylpyridazin(2h)-3-ones |
JPH0753725B2 (ja) | 1987-10-08 | 1995-06-07 | 富山化学工業株式会社 | 4h―1―ベンゾピラン―4―オン誘導体およびその塩、それらの製造法並びにそれらを含有する抗炎症剤 |
JPH01258671A (ja) * | 1987-12-01 | 1989-10-16 | Morishita Pharmaceut Co Ltd | 5−(1h−イミダゾール−1−イル)−3(2h)−ピリダジノン誘導体 |
FI91062C (fi) | 1988-12-28 | 1994-05-10 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisten naftaleenijohdannaisten valmistamiseksi |
EP0530264B1 (en) * | 1990-05-15 | 1996-10-23 | E.I. Du Pont De Nemours And Company | Arthropodicidal tetrahydropyridazines |
IL104369A0 (en) | 1992-01-13 | 1993-05-13 | Smithkline Beecham Corp | Novel compounds and compositions |
JPH08311032A (ja) * | 1995-05-18 | 1996-11-26 | Eisai Co Ltd | α,β−不飽和ケトン誘導体 |
CA2228050A1 (en) | 1995-08-10 | 1997-02-20 | Harold G. Selnick | 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use |
JP2001514669A (ja) | 1997-03-14 | 2001-09-11 | メルク フロスト カナダ アンド カンパニー | シクロオキシゲナーゼ−2阻害薬としてのピリダジノン類 |
ATE319691T1 (de) | 1997-08-22 | 2006-03-15 | Abbott Lab | Prostaglandin endoperoxyde h synthase biosynthese inhibitoren |
CA2299300C (en) | 1997-08-22 | 2007-04-17 | Abbott Laboratories | Arylpyridazinones as prostaglandin endoperoxide h synthase bisoynthesis inhibitors |
CA2307111C (en) * | 1997-11-19 | 2009-06-30 | Kowa Co., Ltd. | Novel pyridazine derivatives and drugs containing the same as the active ingredient |
TWI241295B (en) * | 1998-03-02 | 2005-10-11 | Kowa Co | Pyridazine derivative and medicine containing the same as effect component |
TR200101765T2 (tr) | 1998-10-27 | 2002-02-21 | Abbott Laboratories | Prostaglandin endoperoksit H sentaz biyosentez inhibitörleri |
JP2000247959A (ja) * | 1999-02-26 | 2000-09-12 | Kowa Co | ピリダジン−3−オン誘導体及びこれを含有する医薬 |
US6664256B1 (en) * | 2000-07-10 | 2003-12-16 | Kowa Co., Ltd. | Phenylpyridazine compounds and medicines containing the same |
-
1998
- 1998-11-09 CA CA002307111A patent/CA2307111C/en not_active Expired - Fee Related
- 1998-11-09 EP EP98951732A patent/EP1043317B1/en not_active Expired - Lifetime
- 1998-11-09 MX MXPA00004955A patent/MXPA00004955A/es not_active IP Right Cessation
- 1998-11-09 WO PCT/JP1998/005023 patent/WO1999025697A1/ja not_active Application Discontinuation
- 1998-11-09 DK DK98951732T patent/DK1043317T3/da active
- 1998-11-09 PT PT98951732T patent/PT1043317E/pt unknown
- 1998-11-09 NZ NZ504045A patent/NZ504045A/en unknown
- 1998-11-09 ES ES98951732T patent/ES2324126T3/es not_active Expired - Lifetime
- 1998-11-09 CN CNB988113015A patent/CN1142148C/zh not_active Expired - Fee Related
- 1998-11-09 HU HU0100059A patent/HUP0100059A3/hu unknown
- 1998-11-09 EP EP08019558A patent/EP2017266A1/en not_active Withdrawn
- 1998-11-09 US US09/530,949 patent/US6348468B1/en not_active Expired - Fee Related
- 1998-11-09 DE DE69840755T patent/DE69840755D1/de not_active Expired - Lifetime
- 1998-11-09 RU RU2000115577/04A patent/RU2209813C2/ru not_active IP Right Cessation
- 1998-11-09 ID IDW20000931A patent/ID24166A/id unknown
- 1998-11-09 AU AU97626/98A patent/AU738595B2/en not_active Ceased
- 1998-11-09 BR BR9813998-3A patent/BR9813998A/pt active Search and Examination
- 1998-11-09 KR KR1020007004967A patent/KR100626605B1/ko not_active IP Right Cessation
- 1998-11-09 AT AT98951732T patent/ATE428700T1/de not_active IP Right Cessation
- 1998-11-17 TW TW087119032A patent/TW502025B/zh not_active IP Right Cessation
-
2000
- 2000-04-27 NO NO20002169A patent/NO316021B1/no not_active IP Right Cessation
-
2001
- 2001-05-24 HK HK01103597A patent/HK1032969A1/xx not_active IP Right Cessation
- 2001-11-30 US US09/996,804 patent/US20020123496A1/en not_active Abandoned
-
2004
- 2004-01-15 US US10/757,525 patent/US20040147516A1/en not_active Abandoned
- 2004-11-12 US US10/986,350 patent/US20050065155A1/en not_active Abandoned
-
2005
- 2005-08-15 US US11/203,174 patent/US20050267113A1/en not_active Abandoned
-
2006
- 2006-03-22 US US11/385,995 patent/US20060160804A1/en not_active Abandoned
- 2006-11-01 US US11/590,811 patent/US20070049595A1/en not_active Abandoned
-
2007
- 2007-04-30 US US11/741,947 patent/US20070208025A1/en not_active Abandoned
-
2008
- 2008-01-14 US US12/013,691 patent/US20080119474A1/en not_active Abandoned
- 2008-11-03 US US12/263,816 patent/US20090069332A1/en not_active Abandoned
-
2009
- 2009-07-06 US US12/497,797 patent/US20090270399A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9813998A (pt) | Novos derivados de piridazina e produtos medicinais contendo os mesmos como ingredientes efetivos | |
ATE233250T1 (de) | Saccharinderivate als proteolytische enzyminhibitoren | |
ATE231496T1 (de) | Saccharinderivate als proteolytische enzyminhibitoren | |
NO950297L (no) | Prolinamidderivater | |
TNSN05160A1 (en) | Novel fluoroglycoside heterocyclic derivatives, pharmaceutical products containing said compounds and the use thereof | |
BR0010476A (pt) | Compostos derivados do 4,5,6,7-tetrahidroindazol e seu uso como agentes antitumorais | |
BRPI0509364B8 (pt) | derivados de tetraidroquinolina, composição farmacêutica que os compreende e um processo por preparar os referidos derivados | |
HUP0101461A2 (hu) | Új piridazinszármazékok és az azokat hatóanyagként tartalmazó gyógyszerkészítmények | |
BR9811093A (pt) | Piridinas substituìdas com 2-amino-6-(4-fenóxi 2-substituìdo) | |
NO324219B1 (no) | Fenylpyridazin-forbindelser, medisiner og farmasoytiske preparater inneholdende disse samt anvendelse av disse for fremstilling av medikamenter for behandling av sykdom | |
BR0307071A (pt) | ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico | |
BR0315820A (pt) | Inibidores de integrase de hiv, composições farmacêuticas e métodos para a sua utilização | |
BR0309558A (pt) | Derivados de quinazolina e medicamentos | |
DK223285A (da) | Substituerede bis-(4-aminophenyl)-sulfoner, fremgangsmaade til deres fremstilling og deres anvendelse som laegemiddel | |
DK1194415T3 (da) | Nye piperazinylalkylthiopyrimidinderivater, farmaceutiske sammensætninger indeholdende disse samt en fremgangsmåde til deres fremstilling | |
HUP0101224A2 (hu) | Neuraminidáz inhibitor hatású pirrolidinszármazékok és ezeket a vegyületeket tartalmazó gyógyászati készítmények | |
NO301826B1 (no) | Heterotricyklisk substituerte fenylcykloheksankarboksylsyrederivater, legemidler inneholdende dem og deres anvendelse for fremstilling av legemidler | |
ZA891783B (en) | Peptides with pharmaceutical activity | |
DE60119514D1 (de) | Amidderivate der 2-amino-3-hydroxy-4-tert-leucyl-amino-5-phenyl-pentansäure | |
DK412388A (da) | Leukotrienantagonister, fremgangsmaader og mellemprodukter til deres fremstilling samt deres anvendelse som laegemidler | |
BR9908948A (pt) | Composição farmacêutica contendo um inibidor de protease cisteìna para profilaxia e terapia de dano ao tecido cerebral | |
DK0587048T3 (da) | Heteroarenylpiperaziner, en fremgangsmåde til deres fremstilling og deres anvendelse som lægemidler | |
ZA929974B (en) | Pharmaceutical composition for inhibiting the infection with AIDS virus | |
IL89537A (en) | Di- and tripeptides having inhibitory action on the enzymatic system, their preparation and pharmaceutical compositions containing them | |
GEP20022764B (en) | HIV Protease Inhibitors, Pharmaceutical Compositions and Methods for Inhibiting HIV Protease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: ALTERADO DE INT.CL: C07D 237/04, C07D 237/14, C07D 237/18, C07D 401/04, C07D 401/14, A61K 31/50, A61K 31/501 Ipc: C07D 237/04 (2008.01), C07D 237/14 (2008.01), C07D |
|
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B15V | Prolongation of time limit allowed |
Free format text: DEVOLUCAO DE PRAZO CONCEDIDA - RECONHECIDO O OBSTACULO ADMINISTRATIVO E DEVOLVIDO O PRAZO DE 56 DIAS, NOS TERMOS DO ARTIGO 221 PARAGRAFO 2O DA LPI E DA RESOLUCAO 116/04. |
|
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B11D | Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time |